Jun 08, 2020
Prime Therapeutics and EMD Serono ink value-based agreement on MAVENCLAD® (cladribine) tablets
Feb 17, 2020
Hairy Cell Leukemia Industry Insights by Therapy (2020-2025): Chemotherapy Expected to Register Significant Growth
Feb 06, 2020
EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)
Dec 10, 2019
EMD Serono and the pan-Canadian Pharmaceutical Alliance Complete Negotiations for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis
Oct 07, 2019
Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months
Aug 28, 2019
EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
Aug 12, 2019
Medicines targeting multiple sclerosis and lymphoma are among new specialty drugs available through AllianceRx Walgreens Prime
Jun 26, 2019
With Novartis' Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono's Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure
May 28, 2019
EMD Serono's Mavenclad Edges Past Novartis' Gilenya in the Recent Switch Segment of Canada's Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
May 28, 2019
EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
May 10, 2019
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
Apr 30, 2019
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Apr 10, 2019
Preferential First-Line Use of Biogen's Tecfidera and Continued Uptake of Merck KGaA's Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year
Apr 08, 2019
MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts
Mar 29, 2019
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
Mar 29, 2019
FDA approves new oral treatment for multiple sclerosis
Feb 28, 2019
EMD Serono to Present Multiple Sclerosis Data on Cladribine Tablets and Evobrutinib at ACTRIMS 2019
Dec 11, 2018
Spherix Global Insights' Quarterly Update on the Multiple Sclerosis Market Reveals a Unique Role for Genzyme's Aubagio As the Only Oral Standard-Efficacy Therapy for First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
Oct 10, 2018
MAVENCLAD (Cladribine Tablets) Safety Profile in Multiple Sclerosis (MS) Reaffirmed with up to 10-Years of Follow-up Data
Oct 10, 2018
Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets